U.S. Patent No. 8,871,493 “Transformation system in the field of filamentous fungal hosts”
Jupiter, Fla., November 12, 2014 – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has been issued U.S. Patent No. 8,871,493 “Transformation system in the field of filamentous fungal hosts” by the United States Patent and Trademark Office (“USPTO”).
This issued patent provides broad and extensive intellectual property rights related to Dyadic’s C1 Expression System, which is based on the filamentous fungus Myceliophthora thermophila. The issued claims cover, engineering C1 cell lines, the molecular tools used to engineer these C1 cell lines, as well as genes over expressed in C1 originating from Myceliophthora thermophila, and other organisms. Additionally, the patent covers the development and use of C1 strains to produce proteins and polypeptides, including carbohydrate-degrading enzymes, proteases, lipases, esterases, hydrolases, oxidoreductases, transferases, primary metabolites such as organic acids and secondary metabolites such as antibiotics.
Dyadic’s President and CEO, Mark Emalfarb, stated, “This patent provides wide-ranging and comprehensive intellectual property protection to our C1 Expression System. The applications and methods claimed in this patent further protects Dyadic’s rights to the C1 technology for gene discovery, product development and commercialization of enzymes and other protein products for use in energy, pharmaceutical and industrial markets.”
This patent is the sixteenth U.S. patent issued to Dyadic adding to its portfolio of 38 international patents, 19 pending international and eight pending U.S. patent applications which cover various features of Dyadic’s proprietary technologies.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic’s website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.
CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release are forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) competitive pressures, reliance on key customers and collaborators, obtaining additional debt or equity funding sources; (3) Dyadic’s ability to successfully enforce its intellectual property rights; (4) whether the patented technology will result in any new products or improve Dyadic’s ability to efficiently and effectively develop new products; (5) Dyadic’s research and development efforts; (6) the outcome of the current litigation by Dyadic against its former counsel and (7) other factors discussed in Dyadic’s publicly available filings, including the risk factors included in Dyadic’s Annual Report filed with the OTC Markets Group on March 31, 2014 and our Form 10 registration statement initially filed with the Securities and Exchange Commission on August 15, 2014, as amended.
Dyadic International, Inc.
Thomas L. Dubinski
Chief Financial Officer